Reby Advisors’s AbbVie ABBV Stock Holding History

Reby Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	$73K	Buy	+677	New	+$65.1K	0.02%	179

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Reby Advisors's ABBV Position: Q4 2020 in Review

Reby Advisors opened a new position in AbbVie (ABBV) in Q4 2020: 677 shares worth $73K. The stake represents 0.02% of the portfolio and ranks #179 among its holdings.

2,597 funds tracked by Wall St. Rank hold ABBV as of Q4 2020.

Reby Advisors held 677 shares of AbbVie worth $73K as of Q4 2020.
AbbVie was a new Reby Advisors position in Q4 2020.
AbbVie made up 0.02% of Reby Advisors's portfolio in Q4 2020, its #179 holding.
2,597 funds tracked by Wall St. Rank held AbbVie as of Q4 2020.

Based on Reby Advisors's 13F filing for Q4 2020, filed 12 Feb 2021.